Johnson & Johnson (JNJ) reported positive topline results from the Phase 3 GRAVITI investigational study of TREMFYA subcutaneous induction therapy in adult patients with moderately to severely active Crohn's disease. The study met both co-primary endpoints, achieving statistically significant and clinically meaningful outcomes for clinical remission at Week 12 as well as endoscopic response at Week 12. Safety data from GRAVITI were consistent with the safety profile of TREMFYA in its approved indications.
"The Phase 3 GRAVITI study showed promising results with subcutaneous induction and provides similar clinical benefit to what was seen with IV induction in the GALAXI studies," said David Lee, Global Therapeutic Area Head Immunology, Johnson & Johnson Innovative Medicine.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.